AMAG Pharmaceuticals, Inc.  

(Public, NASDAQ:AMAG)   Watch this stock  
Find more results for AMAG
33.29
-0.49 (-1.45%)
Oct 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 33.18 - 34.33
52 week 16.49 - 34.59
Open 33.93
Vol / Avg. 274,080.00/698,344.00
Mkt cap 741.75M
P/E     -
Div/yield     -
EPS -0.57
Shares 21.96M
Beta 0.07
Inst. own 115%
Oct 27, 2014
Q3 2014 AMAG Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Sep 29, 2014
AMAG Pharmaceuticals, Inc. to Acquire Lumara Health Conference Call - Webcast
Sep 8, 2014
AMAG Pharmaceuticals Inc at Morgan Stanley Healthcare Conference
Sep 3, 2014
AMAG Pharmaceuticals Inc at Robert W. Baird & Co. Inc Health Care Conference - Webcast
Sep 3, 2014
AMAG Pharmaceuticals Inc at FBR & Co Inaugural Healthcare Conference
Aug 6, 2014
AMAG Pharmaceuticals Inc at Jefferies Boston Healthcare Summit: One-on-One Meetings
Jul 29, 2014
Q2 2014 AMAG Pharmaceuticals, Inc. Earnings Release
Jul 29, 2014
Q2 2014 AMAG Pharmaceuticals Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin -6.24% -11.88%
Operating margin 4.98% -14.37%
EBITD margin - -9.22%
Return on average assets -1.39% -3.67%
Return on average equity -3.23% -5.56%
Employees 148 -
CDP Score - -

Address

1100 Winter Street
WALTHAM, MA 02451
United States - Map
+1-617-4983300 (Phone)
+1-617-4993361 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

AMAG Pharmaceuticals, Inc. is a specialty pharmaceutical company that markets Feraheme (ferumoxytol) Injection for Intravenous (IV), used to treat iron deficiency anemia (IDA), in adult patients with chronic kidney disease (CKD), and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucositis. The Company sells Feraheme to authorized wholesalers and specialty distributors, who in turns, sell Feraheme to healthcare providers who administer Feraheme primarily within hospitals, hematology and oncology centers, and nephrology clinics. Its principal source of revenue is from the sale of Feraheme (ferumoxytol) Injection for intravenous (IV). It markets and sells Feraheme in both the dialysis and non-dialysis CKD markets, including to nephrologists, hematologists, dialysis organizations, hospitals and other end-users who treat patients with CKD.

Officers and directors

Gino Santini Chairman of the Board
Age: 57
Bio & Compensation  - Reuters
William K. Heiden President, Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
Frank E. Thomas Chief Operating Officer, Executive Vice President
Age: 44
Bio & Compensation  - Reuters
Scott A. Holmes Senior Vice President - Finance and Investor Relations, Chief Accounting Officer, Treasurer
Age: 39
Bio & Compensation  - Reuters
Scott B. Townsend Senior Vice President - Legal Affairs, General Counsel, Secretary
Age: 47
Bio & Compensation  - Reuters
Edward Jordan Senior Vice President - Sales and Marketing
Age: 46
Bio & Compensation  - Reuters
Steven Caffe M.D. Senior Vice President, Chief Development and Regulatory Officer
Age: 54
Bio & Compensation  - Reuters
Melissa Bradford Klug Senior Vice President - Business Development and Strategy
Bio & Compensation  - Reuters
Robert Blood Esq. Chief Compliance Officer, Vice President - Legal Affairs
Bio & Compensation  - Reuters
Judith Johnson M.D. Vice President - Pharmacovigilance & Pharmacoepidemiology
Bio & Compensation  - Reuters